Evidence map›Paper›PMID 31551048›Full record

ArticleJournal of the Royal Society, Interface2019

Do bevacizumab solutions interact with silicone or polyurethane catheters during an infusion through implantable venous access ports?

Nicolas Tokhadzé, Philip Chennell, Régis Cueff, Valérie Sautou

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the Royal Society, Interface, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nicolas TokhadzéUniversite Clermont Auvergne, CHU Clermont Ferrand, CNRS, Sigma Clermont, ICCF, 63000 Clermont-Ferrand, France.
Philip ChennellUniversite Clermont Auvergne, CHU Clermont Ferrand, CNRS, Sigma Clermont, ICCF, 63000 Clermont-Ferrand, France.
Régis CueffUniversite Clermont Auvergne, CNRS, SIGMA Clermont, ICCF, 63000 Clermont-Ferrand, France.
Valérie SautouUniversite Clermont Auvergne, CHU Clermont Ferrand, CNRS, Sigma Clermont, ICCF, 63000 Clermont-Ferrand, France.
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This work aims to evaluate the possible impact of interactions between bevacizumab solutions and an implantable port equipped with a silicone or a polyurethane catheter after infusion through a complete infusion set-up in simulated use conditions. Physico-chemical and structural stability of bevacizumab solution was assessed by visual examination, subvisible particles counting, dynamic light scattering, size exclusion chromatography and ion exchange chromatography. Mechanical properties of the catheters were evaluated by measuring Shore A hardness, strain at break, strain at stress and Young's modulus. The physico-chemical surface state of the catheters was assessed by FTIR-ATR spectroscopy, scanning electron microscopy (SEM) and by water contact angle measurement. The analysis of the bevacizumab solution did not highlight any signs of instability or loss of active substance. Mechanical properties of both materials remained unchanged after the infusion. During material analysis, a decrease in water contact angle observed after infusion and was more pronounced for polyurethane catheters than for silicone, possibly due to bevacizumab adsorption or possible leachable extraction from the materials. Surface modifications were also noted at SEM. This study did not highlight any modifications that could alter the quality of the bevacizumab infusion, nor of the infusion catheter in polyurethane or silicone, despite a modification of surface hydrophilicity. Even if after a single infusion, implantable ports remained safe to use, they aim to be used for several infusion of various drugs during their lifetime, and further studies are needed to assess the impact of repeated infusions.

Indexed as

BevacizumabCatheterization, Central VenousHumansPolyurethanesSiliconesBevacizumabPolyurethanesSiliconesbevacizumabcathetercontent–container interactionsimplantable venous access portinterfacesstability

Identifiers

PMID31551048
PMCPMC6769320
OpenAlexW2975506637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.